4 Results for "

VTP50469

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "VTP50469" in MCE Product Catalog:

13
13 Publications Verification
Cat. No.: HY-114162
CAS No.: 2169916-18-9
Purity:  99.69%
Synonyms: SNDX-50469
Research Areas:  

Cancer

VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
loading...
    loading...
13
13 Publications Verification
Cat. No.: HY-114162A
CAS No.: 2169919-29-1
Purity:  99.79%
Synonyms: SNDX-50469 fumarate
Research Areas:  

Cancer

VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .
loading...
    loading...
Cat. No.: HY-114162R
CAS No.: 2169916-18-9
Synonyms: SNDX-50469 (Standard)
VTP50469 (Standard) is the analytical standard of VTP50469. This product is intended for research and analytical applications. VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
loading...
    loading...
Cat. No.: HY-114162B
CAS No.: 2169919-27-9
Synonyms: SNDX-50469 mesylate
Research Areas:  

Cancer

VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.
loading...
    loading...